1794 related articles for article (PubMed ID: 16575428)
1. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
Kennedy SH; Andersen HF; Lam RW
J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
[TBL] [Abstract][Full Text] [Related]
2. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
3. Escitalopram in the treatment of major depressive disorder: a meta-analysis.
Kennedy SH; Andersen HF; Thase ME
Curr Med Res Opin; 2009 Jan; 25(1):161-75. PubMed ID: 19210149
[TBL] [Abstract][Full Text] [Related]
4. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
Bielski RJ; Ventura D; Chang CC
J Clin Psychiatry; 2004 Sep; 65(9):1190-6. PubMed ID: 15367045
[TBL] [Abstract][Full Text] [Related]
5. Escitalopram versus venlafaxine XR in the treatment of depression.
Montgomery SA; Andersen HF
Int Clin Psychopharmacol; 2006 Sep; 21(5):297-309. PubMed ID: 16877901
[TBL] [Abstract][Full Text] [Related]
6. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.
Bauer M; Tharmanathan P; Volz HP; Moeller HJ; Freemantle N
Eur Arch Psychiatry Clin Neurosci; 2009 Apr; 259(3):172-85. PubMed ID: 19165525
[TBL] [Abstract][Full Text] [Related]
7. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials.
Einarson TR; Arikian SR; Casciano J; Doyle JJ
Clin Ther; 1999 Feb; 21(2):296-308. PubMed ID: 10211533
[TBL] [Abstract][Full Text] [Related]
8. [Escitalopram for treatment of major depressive disorder in adults].
Llorca PM; Brousse G; Schwan R
Encephale; 2005; 31(4 Pt 1):490-501. PubMed ID: 16389716
[TBL] [Abstract][Full Text] [Related]
9. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.
Llorca PM; Fernandez JL
Int J Clin Pract; 2007 Apr; 61(4):702-10. PubMed ID: 17394446
[TBL] [Abstract][Full Text] [Related]
10. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
Favré P
Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
[TBL] [Abstract][Full Text] [Related]
11. Venlafaxine extended-release: a review of its use in the management of major depression.
Wellington K; Perry CM
CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
[TBL] [Abstract][Full Text] [Related]
12. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
Lam RW; Lönn SL; Despiégel N
Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
[TBL] [Abstract][Full Text] [Related]
13. Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials.
Kornstein SG; Li D; Mao Y; Larsson S; Andersen HF; Papakostas GI
CNS Spectr; 2009 Jun; 14(6):326-33. PubMed ID: 19668123
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Gee MD; Krishen A; Wunderlich HP; Le Clus A; Evoniuk G; Modell JG
J Psychopharmacol; 2010 Aug; 24(8):1209-16. PubMed ID: 19939870
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study.
Kaplan EM
Clin Ther; 2002 Jul; 24(7):1194-200. PubMed ID: 12182262
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies.
de Silva VA; Hanwella R
Int Clin Psychopharmacol; 2012 Jan; 27(1):8-16. PubMed ID: 21971532
[TBL] [Abstract][Full Text] [Related]
17. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
Azorin JM; Llorca PM; Despiegel N; Verpillat P
Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
[TBL] [Abstract][Full Text] [Related]
18. A budget-impact and cost-effectiveness model for second-line treatment of major depression.
Malone DC
J Manag Care Pharm; 2007 Jul; 13(6 Suppl A):S8-18. PubMed ID: 17874482
[TBL] [Abstract][Full Text] [Related]
19. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
Shelton C; Entsuah R; Padmanabhan SK; Vinall PE
Int Clin Psychopharmacol; 2005 Jul; 20(4):233-8. PubMed ID: 15933485
[TBL] [Abstract][Full Text] [Related]
20. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]